Ligand Pharmaceuticals (NASDAQ:LGND) vs. Olema Pharmaceuticals (NASDAQ:OLMA) Head to Head Analysis

Ligand Pharmaceuticals (NASDAQ:LGND) and Olema Pharmaceuticals (NASDAQ:OLMA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings for Ligand Pharmaceuticals and Olema Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0	1	7	0	2.88
Olema Pharmaceuticals	1	2	11	0	2.71

Ligand Pharmaceuticals currently has a consensus target price of $247.29, suggesting a potential upside of 10.77%. Olema Pharmaceuticals has a consensus target price of $44.40, suggesting a potential upside of 169.42%. Given Olema Pharmaceuticals’ higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Institutional & Insider Ownership

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Ligand Pharmaceuticals and Olema Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09 million	16.60	$124.45 million	$5.83	38.29
Olema Pharmaceuticals	N/A	N/A	-$162.45 million	($1.86)	-8.86

Ligand Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ligand Pharmaceuticals has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500.

Profitability

This table compares Ligand Pharmaceuticals and Olema Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	46.42%	13.86%	10.18%
Olema Pharmaceuticals	N/A	-42.95%	-38.78%

Summary

Ligand Pharmaceuticals beats Olema Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.